Log In
Print
BCIQ
Print
Print this Print this
 

AFM13

  Manage Alerts
Collapse Summary General Information
Company Affimed Therapeutics AG
DescriptionTetravalent bispecific human antibody against CD30 and CD16
Molecular Target CD30 ; Fc gamma receptor III (CD16) (FCGR3)
Mechanism of ActionBinds CD30; Binds CD16
Latest Stage of DevelopmentPhase I/II
IndicationHodgkin's disease
Partner

 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today